NEW HAVEN, Conn. --(BUSINESS WIRE)--Sep. 3, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following
Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair loss demonstrated rapid onset and consistent hair growth Completion of patient enrollment for Phase 2/3 Study ‘306’, a 556 participant, registration-directed trial evaluating VDPHL01 in female
NEW HAVEN, Conn. --(BUSINESS WIRE)--Jul. 17, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of
VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as Month 2 and consistent treatment effect with approximately 88.9% (once daily) and 90.0%
Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET NEW HAVEN, Conn. --(BUSINESS WIRE)--Jul. 14, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss,
NEW HAVEN, Conn. --(BUSINESS WIRE)--May 28, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the
NEW HAVEN, Conn. --(BUSINESS WIRE)--May 27, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that topline results from Phase 2/3 ‘302’ Study of
NEW HAVEN, Conn. --(BUSINESS WIRE)--May 14, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that two E-posters will be presented at the 2026
Positive topline results from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first FDA-approved oral treatment for pattern hair loss in nearly 30 years Upsized IPO and follow-on financing generated approximately $766.8 million in aggregate gross proceeds; pro forma cash expected
NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 29, 2026-- Veradermics, Incorporated (“Veradermics”) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the pricing of its upsized public
NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 27, 2026-- Veradermics, Incorporated (“Veradermics”) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that it has launched a proposed
VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 Rapid and robust hair growth was
Conference call will take place on Monday, April 27, 2026 at 8:00 am ET NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 26, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss,